Atreca is a clinical-stage biopharmaceutical company developing novel cancer immunotherapeutics by leveraging deep insights into the human immune response. Its proprietary Immune Repertoire Capture (IRC) technology identifies antibodies generated by the immune systems of cancer patients to discover novel therapeutic targets. Founded in 2010 and based in Redwood City, California, Atreca underwent significant workforce reductions in 2022-2023 while pivoting its pipeline toward antibody-drug conjugates.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2018
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
